Follow

Submissions from 2016

Link

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks, J. J. Feld, C. Moreno, R. Trinh, E. Tam, S. Bourgeois, Y. Horsmans, M. Elkhashab, D. E. Bernstein, N. S. Shulman, F. Poordad, and +7 additional authors

Submissions from 2015

Link

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid, G. M. Hirschfield, A. Mason, V. Luketic, K. Lindor, S. C. Gordon, M. Mayo, K. V. Kowdley, C. Vincent, H. C. Bodhenheimer Jr., D. Shapiro, and +8 additional authors

PDF

Hepatic manifestations of non-steroidal inflammatory bowel disease therapy, R. Hirten, K. Sultan, A. Thomas, and D. E. Bernstein

Link

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders, D. Jensen, K. E. Sherman, C. Hezode, S. Pol, S. Zeuzem, V. de Ledinghen, A. Tran, M. Elkhashab, D. Bernstein, S. Noviello, and +13 additional authors

PDF

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study, D. R. Nelson, J. N. Cooper, J. P. Lalezari, E. Lawitz, P. J. Pockros, N. Gitlin, B. F. Freilich, Z. H. Younes, D. Berastein, E. A. Hughes, and +15 additional authors

Submissions from 2014

Link

ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV, P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, C. Cooper, E. Tam, R. T. Marinho, N. Tsai, K. R. Reddy, and +19 additional authors